Wockhardt shares jump 8% amid high trading volumes, pharma stock extends gains to 45% in one month- Grow Mudra

Wockhardt shares jump 8% amid high trading volumes, pharma stock extends gains to 45% in one month

18 Jun , 2025 By : Debdeep Gupta

The shares of Wockhardt jumped over 8 percent to hit an intraday high of Rs 1,867.90 apiece on June 18. The pharma stock has seen significant surge in recent days, rising nearly 45 percent in one month.

The sharp rise in the share price comes on the back of high trading volumes amid heightened investor interest. Over 35 lakh shares of the company worth around Rs 640 crore were involved in active trade in the first three trading hours of June 18. This is higher than the stock's overall 10-day average volume.

The shares of the company rallied sharply to hit a 52-week high of Rs 1,868.80 apiece on June 12. The stock then corrected slightly in the past few sessions, but saw significant rise again on June 18.

Wockhardt shares remain in focus as investors eye updates on Zaynich, a breakthrough antibiotic against drug-resistant infections. Earlier this month, the company's management had said that the pharma player is planning to file a new drug application (NDA) for Zaynich with the US drug regulator in the second quarter of this fiscal.

"Coming to the United States, there is a very high certainty, I would say, that we should be able to market the product sometime in 2026-27," Wockhardt chairman Habil Khorakiwala told Moneycontrol on the sidelines of an event celebrating the company's 25 years of being listed on the National Stock Exchange of India (NSE).

"We expect Zaynich approval [in India] sometime coming in the beginning of next year, and we should be in the Indian market in the middle of next year," Khorakiwala said.

In Q4FY25, Wockhardt's net loss narrowed to Rs 45 crore, down from Rs 177 crore a year earlier. The improved bottom line was supported by both revenue growth and a recovery in operational performance. The company’s revenue rose to Rs 743 crore in Q4FY25, marking a 6 percent year-on-year increase from Rs 700 crore. On the operational front, Wockhardt posted an EBITDA of Rs 64 crore—a notable turnaround from an EBITDA loss of Rs 103 crore in Q4FY24. This marks a return to positive operating margins, indicating tighter cost control and stronger performance across key markets.